2025 H2 -tulosraportti
27 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 695 | - | - | ||
| 286 | - | - | ||
| 412 | - | - | ||
| 76 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sittenAs well pointed out by @Gandalf Pengeklok, "Qube Research & Technologies (QRT)" has taken a short position of 1,823,405 shares (0.50%) in TRMED as of March 24, 2026, reported to Finanstilsynet. Worth knowing who QRT is before worrying: This is one of the world's largest quant funds ($42 bn under management), spun out from Credit Suisse in 2018. They delivered ~30% return in 2025. The team consists of physicists, mathematicians, and data scientists who trade exclusively based on algorithms and statistical models, i.e., NOT fundamental analysis of the company's operations!! A QRT short therefore does not mean that someone has analyzed AlphaOne, the AdvanCell agreement, or the Lilly connection and concluded that TRMED is overvalued. It means that a model has seen a pattern in the price movement, and that's all. Such positions can be gone again within days, and it implies nothing negative about TRMED as a company long-term. 0.50% is also not an aggressive short position. Even if they were «right» and we dump a bit in price, it's still irrelevant, keep a cool head. The fundamentals are unchanged.
·2 t sittenNew short position from qube research
·2 t sitten · MuokattuBriefly about Qube Research & Technologies. They are a London-based (with offices in several locations) quant-driven investment company. They use advanced algorithms, data analysis, and quantitative models for both long and short positions. Possibly they have underestimated Trmed here, where they have only looked at the charts in recent weeks as well as price targets.- ·3 t sitten · MuokattuJasper Kurth goes on stage in China tomorrow at 10.00 to talk about the increasing interest in Lead -212 and Thor Medical's role in the Targedet Alpha Therapy - landscape. «Thor Medical is a pioneer in the Thorium to therapy approach - a reactor-free model that draws alpha emitters directly from natural Thorium decay chains. Decentralized potential - a robust,scalable supply model that is custom-built for markets like Asia, where Centralized logistics most acutely exacerbates the half-life. Thor Medical's Model is not just a supply chain upgrade - it could be the infrastructure that ultimately turns Pb-212 into a Commercial Standard. For CDMP partners who are ready to receive and formulate it on a large scale, the window opens.» XDC Conference Chengdu 26-26 March.·2 t sittenMaybe you can follow along here ->. https://www.youtube.com/@XOrgFoundation/videos
·5 t sittenMany here seem keen on partnerships in Asia, but I don't think it's directly linked to Herøya. Herøya is the prototype. If we are to enter the Asian market, we are probably more at an "Alpha Asia" level. The reason is actually quite simple.. Half-life of around 10 hours. This is a perishable product, you can't send it from Herøya to China and expect everything to be the same when it arrives. Then both the effect and the economics quickly fail. Therefore, local production over there makes much more sense than flying halfway around the globe. And that the CEO is there now is actually quite bullish in my eyes. It indicates that they are close to the market and exploring opportunities, not just sitting at Herøya and hoping. So yes, Asia is exciting. But not because we are going to export from Norway. Herøya is the starting shot. Not the finish line itself. The rest is about execution 😁😁- ·8 t sittenI believe and think that towards closing time today it will rise a little, because the profitability/risk for tomorrow in China in relation to new customers or investors is super. If nothing new comes, then fine, it changes nothing. But if something were to emerge, then this will rise considerably. Regardless, it is positive that Thor opens the island to other countries that have many people and most likely a great need for this type of raw material that is in short supply in the world.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
27 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenAs well pointed out by @Gandalf Pengeklok, "Qube Research & Technologies (QRT)" has taken a short position of 1,823,405 shares (0.50%) in TRMED as of March 24, 2026, reported to Finanstilsynet. Worth knowing who QRT is before worrying: This is one of the world's largest quant funds ($42 bn under management), spun out from Credit Suisse in 2018. They delivered ~30% return in 2025. The team consists of physicists, mathematicians, and data scientists who trade exclusively based on algorithms and statistical models, i.e., NOT fundamental analysis of the company's operations!! A QRT short therefore does not mean that someone has analyzed AlphaOne, the AdvanCell agreement, or the Lilly connection and concluded that TRMED is overvalued. It means that a model has seen a pattern in the price movement, and that's all. Such positions can be gone again within days, and it implies nothing negative about TRMED as a company long-term. 0.50% is also not an aggressive short position. Even if they were «right» and we dump a bit in price, it's still irrelevant, keep a cool head. The fundamentals are unchanged.
- ·2 t sittenNew short position from qube research·2 t sitten · MuokattuBriefly about Qube Research & Technologies. They are a London-based (with offices in several locations) quant-driven investment company. They use advanced algorithms, data analysis, and quantitative models for both long and short positions. Possibly they have underestimated Trmed here, where they have only looked at the charts in recent weeks as well as price targets.
- ·3 t sitten · MuokattuJasper Kurth goes on stage in China tomorrow at 10.00 to talk about the increasing interest in Lead -212 and Thor Medical's role in the Targedet Alpha Therapy - landscape. «Thor Medical is a pioneer in the Thorium to therapy approach - a reactor-free model that draws alpha emitters directly from natural Thorium decay chains. Decentralized potential - a robust,scalable supply model that is custom-built for markets like Asia, where Centralized logistics most acutely exacerbates the half-life. Thor Medical's Model is not just a supply chain upgrade - it could be the infrastructure that ultimately turns Pb-212 into a Commercial Standard. For CDMP partners who are ready to receive and formulate it on a large scale, the window opens.» XDC Conference Chengdu 26-26 March.·2 t sittenMaybe you can follow along here ->. https://www.youtube.com/@XOrgFoundation/videos
- ·5 t sittenMany here seem keen on partnerships in Asia, but I don't think it's directly linked to Herøya. Herøya is the prototype. If we are to enter the Asian market, we are probably more at an "Alpha Asia" level. The reason is actually quite simple.. Half-life of around 10 hours. This is a perishable product, you can't send it from Herøya to China and expect everything to be the same when it arrives. Then both the effect and the economics quickly fail. Therefore, local production over there makes much more sense than flying halfway around the globe. And that the CEO is there now is actually quite bullish in my eyes. It indicates that they are close to the market and exploring opportunities, not just sitting at Herøya and hoping. So yes, Asia is exciting. But not because we are going to export from Norway. Herøya is the starting shot. Not the finish line itself. The rest is about execution 😁😁
- ·8 t sittenI believe and think that towards closing time today it will rise a little, because the profitability/risk for tomorrow in China in relation to new customers or investors is super. If nothing new comes, then fine, it changes nothing. But if something were to emerge, then this will rise considerably. Regardless, it is positive that Thor opens the island to other countries that have many people and most likely a great need for this type of raw material that is in short supply in the world.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 695 | - | - | ||
| 286 | - | - | ||
| 412 | - | - | ||
| 76 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
27 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenAs well pointed out by @Gandalf Pengeklok, "Qube Research & Technologies (QRT)" has taken a short position of 1,823,405 shares (0.50%) in TRMED as of March 24, 2026, reported to Finanstilsynet. Worth knowing who QRT is before worrying: This is one of the world's largest quant funds ($42 bn under management), spun out from Credit Suisse in 2018. They delivered ~30% return in 2025. The team consists of physicists, mathematicians, and data scientists who trade exclusively based on algorithms and statistical models, i.e., NOT fundamental analysis of the company's operations!! A QRT short therefore does not mean that someone has analyzed AlphaOne, the AdvanCell agreement, or the Lilly connection and concluded that TRMED is overvalued. It means that a model has seen a pattern in the price movement, and that's all. Such positions can be gone again within days, and it implies nothing negative about TRMED as a company long-term. 0.50% is also not an aggressive short position. Even if they were «right» and we dump a bit in price, it's still irrelevant, keep a cool head. The fundamentals are unchanged.
- ·2 t sittenNew short position from qube research·2 t sitten · MuokattuBriefly about Qube Research & Technologies. They are a London-based (with offices in several locations) quant-driven investment company. They use advanced algorithms, data analysis, and quantitative models for both long and short positions. Possibly they have underestimated Trmed here, where they have only looked at the charts in recent weeks as well as price targets.
- ·3 t sitten · MuokattuJasper Kurth goes on stage in China tomorrow at 10.00 to talk about the increasing interest in Lead -212 and Thor Medical's role in the Targedet Alpha Therapy - landscape. «Thor Medical is a pioneer in the Thorium to therapy approach - a reactor-free model that draws alpha emitters directly from natural Thorium decay chains. Decentralized potential - a robust,scalable supply model that is custom-built for markets like Asia, where Centralized logistics most acutely exacerbates the half-life. Thor Medical's Model is not just a supply chain upgrade - it could be the infrastructure that ultimately turns Pb-212 into a Commercial Standard. For CDMP partners who are ready to receive and formulate it on a large scale, the window opens.» XDC Conference Chengdu 26-26 March.·2 t sittenMaybe you can follow along here ->. https://www.youtube.com/@XOrgFoundation/videos
- ·5 t sittenMany here seem keen on partnerships in Asia, but I don't think it's directly linked to Herøya. Herøya is the prototype. If we are to enter the Asian market, we are probably more at an "Alpha Asia" level. The reason is actually quite simple.. Half-life of around 10 hours. This is a perishable product, you can't send it from Herøya to China and expect everything to be the same when it arrives. Then both the effect and the economics quickly fail. Therefore, local production over there makes much more sense than flying halfway around the globe. And that the CEO is there now is actually quite bullish in my eyes. It indicates that they are close to the market and exploring opportunities, not just sitting at Herøya and hoping. So yes, Asia is exciting. But not because we are going to export from Norway. Herøya is the starting shot. Not the finish line itself. The rest is about execution 😁😁
- ·8 t sittenI believe and think that towards closing time today it will rise a little, because the profitability/risk for tomorrow in China in relation to new customers or investors is super. If nothing new comes, then fine, it changes nothing. But if something were to emerge, then this will rise considerably. Regardless, it is positive that Thor opens the island to other countries that have many people and most likely a great need for this type of raw material that is in short supply in the world.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 | - | - | ||
| 695 | - | - | ||
| 286 | - | - | ||
| 412 | - | - | ||
| 76 | - | - |
Välittäjätilasto
Dataa ei löytynyt